Affordable Access

Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours.

Authors
  • Mathé, G
  • Serrou, B
  • Hayat, M
  • De Vassal, F
  • Misset, J L
  • Schwarzenberg, L
  • Machover, D
  • Ribaud, P
  • Belpomme, D
  • Jasmin, C
  • Musset, M
  • Montero, J L
  • Imbach, J L
Type
Published Article
Journal
Biomedicine / [publiée pour l'A.A.I.C.I.G.]
Publication Date
Nov 01, 1977
Volume
27
Issue
8
Pages
294–297
Identifiers
PMID: 339971
Source
Medline
License
Unknown

Abstract

RFCNU or (chloro-2-ethyl)-l-(ribofuranosyl-isopropylidene-2', 3' paranitrobenzoate-5')-3 nitrosourea, a new synthetic nitrosourea derivative, which has been shown to have, in mice, among all nitrosourea derivatives tested, the longest maximallly efficient dose interval (MEDI) and which is not immunosuppressive at the smallest dose of MEDI, gave in a phase II trial on digestive tract tumours (at the dose of 400 mg/m2 per month determined by the phase I trial), 30% objective remissions among which 13% were greater than 50%.

Report this publication

Statistics

Seen <100 times